Overview of S-RBD Antibody Levels After Covid-19 Vaccination in Premenopausal and Menopausal Women

  • Juminten Saimin Faculty of Medicine Halu Oleo University Kendari
  • Irawaty Universitas Halu Oleo
  • Nur Indah Purnamasari Universitas Halu Oleo
  • Yenti Purnamasari Universitas Halu Oleo
  • Sufiah Asri Mulyawati Universitas Halu Oleo

Abstract

Objective: To determine the levels of S-RBD antibodies in premenopausal and postmenopausal women who received the COVID-19 vaccine.

Methods: This study involved 21 premenopausal and postmenopausal women who received two doses of CoronaVac at 28 days intervals. The duration of vaccination was 4-24 weeks. This study was conducted on May–October 2021 in Kendari City, Indonesia. Blood samples were taken at a health care facility and examined at the Prodia Clinical Laboratory. Participants were healthy women, willing to participate, and signed informed consent. Participants were excluded if they had a history of COVID-19, had taken antibiotics or immunomodulators in the last 24 hours, had a history of acute/chronic inflammatory disease and malignancy, were traumatized and received monoclonal antibody therapy.

Results: Participants were 52.95±7.61 years old. The duration of the second vaccination was 13.67±5.26 weeks. The lowest level of S-RBD antibody was menopause with vaccination duration <=12 weeks (185.59±112.34 U/mL), and the highest was premenopause with vaccination duration >12 weeks (257.5±3.54 U/mL). The S-RBD antibody level in premenopausal women was higher than in menopausal women at the duration of vaccination <=12 weeks  (223.37±63.45 vs 185.59±112.34 U/mL) and >12 weeks (257.5±3.54 vs. 225.55±91.14 U/mL). There was no significant difference in S-RBD antibody levels between two or more groups (p>0.05).

Conclusion: S-RBD antibody levels in postmenopausal women after receiving two doses of COVID-19 vaccine were lower than in premenopausal women, but the difference was not significant. S-RBD antibody levels in postmenopausal women increased with increasing duration of vaccine administration.

Keywords: menopause, immune response, COVID-19 vaccine, S-RBD antibody

Downloads

Download data is not yet available.

Author Biographies

Irawaty, Universitas Halu Oleo

Department of Biomedicine

Nur Indah Purnamasari, Universitas Halu Oleo

Department of Obstetrics and Gynecologic

Yenti Purnamasari, Universitas Halu Oleo

Department of Biomedicine

Sufiah Asri Mulyawati, Universitas Halu Oleo

Department of Biomedicine

Published
2023-02-02
Section
Research Article